Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases

Abstract : Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom the prognosis remains poor, especially when metastases are present at diagnosis. Because we recently demonstrated that TGF-β/Smad cascade plays a crucial role in osteosarcoma metastatic progression, we investigated the effect of halofuginone, identified as an inhibitor of the TGF-β/Smad3 cascade, on osteosarcoma progression. A preclinical model of osteosarcoma was used to evaluate the impact of halofuginone on tumor growth, tumor microenvironment and metastasis development. In vivo experiments showed that halofuginone reduces primary tumor growth and lung metastases development. In vitro experiments demonstrated that halofuginone decreases cell viability mainly by its ability to induce caspase-3 dependent cell apoptosis. Moreover, halofuginone inhibits the TGF-β/Smad3 cascade and the response of TGF-β key targets involved in the metastases dissemination process such as MMP-2. In addition, halofuginone treatment affects the "vicious cycle" established between tumor and bone cells, and therefore the tumor-associated bone osteolysis. Together, these results demonstrate that halofuginone decreased primary osteosarcoma development and associated lung metastases by targeting both the tumor cells and the tumor microenvironment. Using halofuginone may be a promising therapeutic strategy against tumor progression of osteosarcoma specifically against lung metastases dissemination.
Liste complète des métadonnées

Littérature citée [36 références]  Voir  Masquer  Télécharger
Contributeur : Sandrine Maurice <>
Soumis le : mercredi 16 mai 2018 - 16:01:26
Dernière modification le : jeudi 17 mai 2018 - 01:25:38
Document(s) archivé(s) le : mercredi 26 septembre 2018 - 01:34:19


Fichiers éditeurs autorisés sur une archive ouverte




Audrey Lamora, Mathilde Mullard, Jérôme Amiaud, Régis Brion, Dominique Heymann, et al.. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases. Oncotarget, Impact journals, 2015, 6 (16), pp.14413-27. 〈10.18632/oncotarget.3891〉. 〈inserm-01793498〉



Consultations de la notice


Téléchargements de fichiers